ROS1 Lung Cancer Drug Ibtrozi May Improve Breathing and Quality of Life

For patients living with a rare form of lung cancer, the goal of treatment is often two-fold: stopping the tumor and feeling well enough to enjoy daily life. New data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting suggests that a targeted therapy called Ibtrozi (taletrectinib) is helping patients with ROS1-positive non-small cell lung cancer achieve both.

The findings come from the TRUST-II study, a global clinical trial evaluating how Ibtrozi impacts the lived experience of patients. Unlike traditional chemotherapy, Ibtrozi is a next-generation targeted drug designed to specifically block the ROS1 protein that drives cancer growth. Importantly, it is also CNS-active, meaning it can reach the brain, a common site where this type of lung cancer spreads.

Feeling better, faster

One of the most encouraging aspects of the study for patients is how quickly the drug may provide relief from burdensome symptoms. Researchers tracked patient-reported outcomes, which are essentially surveys where patients describe how they feel in their own words.

For patients who had never received a targeted drug before, a troublesome cough improved in a median of 23 days, roughly three weeks after starting treatment. Other common symptoms, such as shortness of breath and fatigue, showed significant improvement within about six weeks for the overall group.

By the time patients reached their second month of treatment, between 84% and 96% reported that their coughing and breathing issues had either improved or remained stable.

Prioritizing brain health and daily life

Because ROS1-positive lung cancer often moves to the brain, patients and doctors are frequently concerned about cognitive function —the ability to think, remember and concentrate. The TRUST-II data showed that mean cognitive function scores remained stable throughout the treatment.

In fact, the study found that 63% to 77% of patients reported their ability to think clearly either improved or stayed the same while taking the drug. Only a small percentage of patients saw any worsening in this area.

General quality of life also remained high. Among patients who had previously been treated with other targeted drugs, 93% reported that their overall health and quality of life improved or stayed stable by their first check-up on the new medication.

A long-term strategy

The benefits of the drug appeared to last well beyond the first few weeks. On average, patients maintained their improvements in pain, fatigue and breathing for about eight months.

"[Ibtrozi] was associated with improved or stable health-related quality of life in the majority of patients," the study authors concluded in their poster presentation of their data.

For the patient community, these results offer hope that modern targeted therapies can do more than just shrink tumors; they can help preserve the ability to breathe easier and maintain a clear mind for longer periods. As research continues, this focus on the patient’s actual daily experience remains a vital part of the conversation in cancer care.

Reference

1. “Patient-reported outcomes and health-related quality of life with taletrectinib in advanced ROS1+ NSCLC from the TRUST-II study” by Dr. Yasir Y. Elamin et al., poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29 – June 2, 2026; Chicago, IL. Abstract 8529.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.